Intentional weight loss via semaglutide among persons with heart failure and preserved ejection fraction and obesity significantly improves weight loss and health status as assessed by the KCCQ-CSS score and is associated with improvements in 6-min walk test. Ongoing and planned trials will explore the role of intentional weight loss with treatments such as semaglutide or tirzepatide for individuals with heart failure across the entire ejection fraction spectrum.
Keyphrases
- weight loss
- ejection fraction
- heart failure
- bariatric surgery
- aortic stenosis
- roux en y gastric bypass
- gastric bypass
- left ventricular
- weight gain
- acute heart failure
- cardiac resynchronization therapy
- glycemic control
- atrial fibrillation
- obese patients
- metabolic syndrome
- insulin resistance
- body mass index
- physical activity
- aortic valve